Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02900157 | Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors | PHASE1 | COMPLETED | 42 | — | — | Aug 9, 2016 | Jan 23, 2020 | Jan 14, 2021 | 8 | United States, Japan |
| Arm | Type | Description |
|---|---|---|
| MEDI9090 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MEDI9090 | BIOLOGICAL | MEDI9090 will be administered by IV infusion |
| Durvalumab | BIOLOGICAL | Durvalumab as a single agent will be administered by IV infusion after patients have completed the prescribed doses of Medi9090. |
Inclusion Criteria: * Male and female subjects * 18 years and older * Must have histologic documentation of advanced solid tumors * Must have received and have progressed, are refractory or, intolerant to standard therapy and must not have a curative therapy option Exclusion Criteria: * Concurren...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |